News articles about Ultragenyx Pharmaceutical (NASDAQ:RARE) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.0277741915428 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $50.81 on Friday. The stock has a market cap of $2,142.66, a PE ratio of -7.29 and a beta of 1.83. Ultragenyx Pharmaceutical has a 52-week low of $43.14 and a 52-week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.87). The company had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.02 million. Ultragenyx Pharmaceutical’s quarterly revenue was up 81.8% on a year-over-year basis. During the same period last year, the firm earned ($1.64) earnings per share. analysts anticipate that Ultragenyx Pharmaceutical will post -7.3 EPS for the current year.

A number of research firms have recently weighed in on RARE. Morgan Stanley restated an “equal weight” rating and issued a $71.00 target price (up from $69.00) on shares of Ultragenyx Pharmaceutical in a report on Friday, October 6th. Robert W. Baird restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 19th. Jefferies Group upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and boosted their target price for the stock from $58.00 to $72.00 in a report on Monday, December 4th. Barclays boosted their target price on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 5th. Finally, Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $72.40.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/06/ultragenyx-pharmaceutical-rare-getting-somewhat-positive-media-coverage-study-shows.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related stocks with our FREE daily email newsletter.